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Background: Nowadays, evaluation of colorectal cancer prognosis and decision-making for treatment continues to
be based primarily on TNM tumour stage. Administration of adjuvant chemotherapy is especially challenging for
stage II patients that can have very different disease-related outcomes. Therefore, more reliable prognostic markers
need to be developed to improve the selection of stage II patients at high risk for recurrence. Our purpose is to
assess the prognostic value of preoperative serum CA 72.4 to improve the risk stratification of CRC patients.
Methods: Preoperative sera collected from 71 unselected patients between January 1994 and February 1997 was
assayed for CA 72.4 and CEA levels. Patients were followed-up for at least 30 months or until relapse. Survival curves
were estimated by the Kaplan-Meier method and the prognostic value was determined using Log-Rank test and
Cox regression analysis.
Results: Preoperative CA 72.4 levels above 7 U/mL correlate with a worse prognosis, with associated recurrence
and death percentages exceeding the displayed by CEA. In a multivariate analysis, its combination with CEA proved
the most important independent factor predicting survival. Remarkably, at stage II CA 72.4 also discriminates better
than CEA those patients that will relapse or die from those with a favourable prognosis; however, CEA has not a
negligible effect on survival.
Conclusions: The most outstanding finding of the present work is the correct classification of nearly every patient
with bad prognosis (relapse or death) at TNM stage II when CEA and CA 72.4 are used altogether. This could
improve the decision-making involved in the treatment of stage II colon cancer. Certainly further large-scale studies
must be performed to determine whether CA 72.4 can be effectively used in the clinical setting.
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Colorectal cancer (CRC) is the principal in Europe and
the third in United States most commonly diagnosed ma-
lignancy in both sexes, and rates second and third origin
of cancer-related death in those areas, respectively [1,2].
Long has been investigated to propose novel useful
independent prognosticators for CRC [3,4], however,
none has been yet integrated into routine practice and
prognosis remains an unresolved question in CRC* Correspondence: mpaez@uvigo.es
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reproduction in any medium, provided the ormanagement. Consequently, although some improve-
ment in CRC survival has been recently achieved due
to advances in diagnostic and surgical procedures, it
continues to be poor [5,6].
At the moment, prognosis for CRC relies mainly on
tumour stage [7,8]. Furthermore, the decision of giving ad-
juvant chemotherapy is based primarily on tumour stage
too, except for advanced disease, where some improvement
is seen towards more personalized, tumour-specific treat-
ment [9]. TNM (Tumour, Node and Metastasis) stage I
disease carries an excellent prognosis, approximately 93%
5-year survival rate [10], and at present there are no con-
vincing data to support adjuvant chemotherapy for patientsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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exhibiting survival rates of 44-83% [10], post-operative
chemotherapy is recommended as standard therapy pro-
vided its value improving disease free (DFS) and overall
survival (OS) [12]. Conversely, patients bearing stage II
TNM tumours, with 5-year survival rates ranging from 72
to 85% [10], can experience very different disease-related
outcomes and meta-analyses regarding effectiveness of ad-
juvant therapy in this setting are controversial [12,13].
While some patients experience full recovery after surgical
removal of the tumour, others suffer from disease recur-
rence and metastasis. Thus, the risk exists that patients
who would be cured with surgery alone are being subjected
to the toxicity of chemotherapy. In this scenario, adminis-
tration of adjuvant chemotherapy to stage II patients repre-
sents the most challenging aspect in the treatment of
colon cancer today [14].
We present and discuss new results regarding the
value of preoperative serum Carbohydrate Antigen CA
72.4, CA 72.4, in the prognosis of CRC to improve the
risk stratification of patients. CA 72.4 has been previ-
ously proposed as a serum prognostic tumour marker in
gastrointestinal malignancies [15-18].
We have also compared and combined the value of
CA 72.4 with the most widely used serum prognostic
tumour marker in colorectal cancer, Carcinoembryonic
Antigen, CEA, [19-21], and checked whether they repre-
sent independent prognostic factors regarding the TNM
classification and other patient and tumour features.
Our results suggest that it is worthy to determine pre-
operative levels of CA 72.4 for an accurate distinction of
high-risk patients that should be given chemotherapy, and
of low-risk patients who will not have recurrent disease.
Methods
Patient and tumour characteristics
Preoperative blood was collected from 137 consecutive
unselected patients between January 1994 and February
1997, operated for CRC at “Complejo Hospitalario
Universitario de Vigo”, Spain. Whole surgical specimens
from tumour and normal mucosa were also obtained from
the same patients.
The study was approved by the Ethical Committee of
“Complejo Hospitalario Universitario de Vigo” and followed
the clinical-ethical practices of the Spanish Government,
complied with the Helsinki Declaration, Oviedo Agree-
ment, the Organic Law for Data Protection 15/1999, and
Royal Decree 1720/2007. All participants gave informed
consent to provide samples and anonymity was warranted
using clinical history numbers.
For survival analyses, exclusion criteria included: death
within 30 days of surgery, administration of adjuvant ther-
apy either pre- or post-operatively (with the exception of
radiotherapy in rectum carcinoma patients), presence ofextraganglionar metastases, failure to resect the whole
tumour mass, presence of familial adenomatous polyposis
coli, inflammatory bowel disease, no adenocarcinoma
histology or previous CRC.
Complete prognostic information was obtained on 71
potentially cured patients, TNM stages I-III, that satis-
fied the inclusion criteria. These patients were followed-
up for at least 30 months or until relapse.
The patient group consisted of 38 men and 33
women, with a mean age of 67 (ranging 41–87). The
primary tumour location was the colon for 46 patients
and the rectum for 25. Regarding tumour grade 4 pa-
tients had well differentiated tumours, 61 moderately
differentiated tumours and 6 patients presented poorly
differentiated tumours. TNM classification was applied
to define tumour stage, as follows: 9 patients were
classified as having TNM I tumours, 40 patients with
TNM II and 22 patients with TNM III.
TNM classification
All primary colorectal tumours were adenocarcinoma.
Surgical specimens were processed for regular patho-
logical and histological examination. Stage of disease
was reported according to TNM classification [22].
Preparation of samples
The drawn blood was allowed to coagulate at room
temperature and centrifuged at 2000 g for 15 min. The
sera obtained were stored at −85°C until analysis.
Tumour markers assays
CEA and CA 72.4 were analysed in serum using the
commercial immunoassays Enzymun-Test© CEA and
Enzymun-Test© CA 72.4 (Boehringer Mannhein,
Mannhein). For CA 72.4 we have used a cut-off value
of 7 U/mL, and for CEA 10 ng/mL, following the
clinical routine at the Hospital and in accordance
with other authors [23].
Statistical methods
A postoperative follow-up of the patients was carried
out in order to evaluate the impact of each tumour
marker on the disease free survival (D.F.S) and the
overall survival (O.S.). Survival curves were estimated
by the univariate Kaplan-Meier method. DFS and OS
were defined as the time interval from the initial event
(curative surgery) to the respective end-points (relapse
or death), as well as the time interval from the initial
event to the last surveillance date for patients that had
not suffered relapse or death. To check the significant
differences in the curves among groups the Log-Rank
test was applied. Furthermore, univariate and multi-
variate Cox analysis were performed. All tests were car-
ried out using the Statistical Package for the Social
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were considered statistically significant.
Results
A survival study was carried out in 71 curatively
tumour resected colorectal cancer patients. After a
mean post-operative follow-up period of 44 months, 17
patients presented recurrence (23.9%) and 11 finally
died (15.5%). The mean DFS and OS were of 52.42 and
57.37 months, respectively.
Analysis of the survival stratified by patients and tumours
characteristics
Survival was first analysed regarding the following pa-
tient and tumour features: age, gender, location of the
tumour, TNM stage and tumour differentiation (data on
Additional file 1).
To determine whether age affects survival a cut-off
point of 75 years was established. Patients older than
75 years exhibited worse prognosis, mainly in relation
to OS that was 51.32 months, with a death percentage
of 26.32%, while these data were of 59.32 months and
11.54%, respectively, for patients ≤75 years. This differ-
ence in OS did not reach statistical significance, al-
though it was near to be significant (P = 0.082).
Gender distribution was not responsible for statistical
differences in prognosis, even though women presented
slightly superior recurrence and death rates.
Regarding the location of the primary tumour, both DFS
and OS were higher for colon cancer patients. However,
only divergence in DFS was near to the significance (P =
0.063), with mean values of 56.14 months and associated
tumour recurrence rates of 17.39% versus 36%.
To analyse influence of TNM classification on survival,
we studied DFS and OS at every TNM stage. The applica-
tion of Log-Rank test rendered highly significant differ-
ences for DFS (P = 0.025) as well as for OS (P = 0.043). A
TNM stage progressively more advanced correlates with a
worse prognosis, both for the DFS and the OS. So, at
TNM stage I recurrence was observed for just one patient
and no deaths were reported, while stage II patients show
percentages of tumour recurrence and death of 17.5% andTable 1 DFS and OS rates stratified by tumour markers and u
D.F.S.
Tumour marker Levels n Mean
(Months)
Recurrence% M
(M
CA 72.4 ≤ 7 60 57.12 15.00 6
U/mL > 7 11 24.11a 72.73 3
CEA ≤ 10 57 56.01 17.54 5
ng/mL > 10 14 31.03b 50.00 3
Abbreviations: DFS, disease free survival; OS, overall survival; RH, relative hazard; 95%
aP <0.0001, bP = 0.004, cP = 0.01, dP = 0.007, eP = 0.02.12.5% respectively, with mean DFS and OS of 55.73 and
58.55 months. Lastly, percentages of tumour recurrence
and death at stage III increase to 40.9% and 27.3% re-
spectively, with an associated DFS of 39.05 months and
OS of 47.13 months.
Influence of tumour differentiation on survival was
also evaluated. Survival was progressively worse from
well to moderately and above all in poorly differenti-
ated adenocarcinoma, resulting an OS statistically in-
ferior (P = 0.009); recurrence was observed in 50% of
patients bearing poorly differentiated tumours, while it
was of 13.1% in moderately differentiated tumours and
0% in well differentiated tumours.
Analysis of the survival of patients stratified by tumour
markers
DFS and OS were analysed in patients stratified accord-
ing to preoperative serum CA 72.4 and CEA levels,
employing the most widely used cut-off points in clinical
routine. Significant differences arised both for CA 72.4
and CEA regarding DFS as well as OS.
Table 1 reports mean DFS and OS periods, and per-
centages of tumour recurrence and death for the two
markers in each group under analysis. Patients with pre-
operative serum CA 72.4 levels above the threshold of 7
U/mL exhibit recurrence and death percentages of 72.73
and 63.64%, with a mean DFS and OS of 24.11 and
31.17 months, respectively. Notably, death rate was only
6.67% for CA 72.4 levels below the cut-off. Recurrence
and death rates were of 50.0% and 35.71% in patients
with preoperative CEA levels over 10 ng/mL, associated
with longer survival times than in the case of CA 72.4.
To establish the recurrence and death relative hazards a
univariate Cox analysis was performed. Results show that
increased CA 72.4 levels imply a recurrence relative haz-
ard of 7.98 and death relative hazard of 13.37, double and
three times higher than hazards for increased CEA levels.
Analysis of the survival of patients stratified by the
positivity of tumour markers
Survival was also assessed for all patients taking into
account the number of altered tumour markers, demonstratingnivariate Cox analysis in all patients
O.S. Univariate Cox analysis
ean
onths)
Death% Recurrence Death
RH 95% CI RH 95% CI
1.23 6.67 1.00 (ref) 1.00 (ref)
1.17a 63.64 7.98 (3.03-21.00)a 13.37 (3.89-45.92)a
9.73 10.53 1.00 (ref) 1.00 (ref)
7.57c 35.71 3.78 (1.43-10.01)d 4.12 (1.26-13.57)e
CI, 95% confidence interval; ref, reference.
Table 2 DFS and OS rates stratified by positivity of tumour markers and univariate Cox analysis
D.F.S. O.S. Univariate Cox analysis
Positive markers n Mean
(Months)
Recurrence% Mean
(Months)
Death% Recurrence Death
RH 95% CI RH 95% CI
None 51 59.02 11.8 62.49 3.9 1.00 (ref) 1.00 (ref)
1 15 31.67 46.7 37.52 40.0 5.67 (1.88-17.13)b 12.34 (2.48-61.35)b
2 5 23.65 a 80.0 30.23 a 60.0 11.59 (3.24-41.48)c 23.86 (3.97-143.58)d
Abbreviations: DFS, disease free survival; OS, overall survival; RH, relative hazard; 95% CI, 95% confidence interval; ref, reference.
aP <0.0001, bP = 0.002, cP = 0.0002, dP = 0.0005.
Ayude et al. BMC Cancer 2013, 13:543 Page 4 of 8
http://www.biomedcentral.com/1471-2407/13/543striking differences for DFS as well as for OS when one or
the two markers presented increased levels (Table 2).
We observed that patients with normal levels of both CA
72.4 and CEA show low tumour recurrence and death rates
of 11.8% and 3.9%, with a mean DFS and OS of 59.02 and
62.49 months, respectively. When one of the tumour
markers exhibits increased levels the percentages of tumour
recurrence and death grow to 46.7% and 40.0% (DFS and
OS of 31.67 and 37.52 months), and they are dramatically
increased to 80.0% and 60.0% when both markers have
their levels elevated, accompanied by a reduced mean DFS
of 23.65 months and OS of 30.23 months.
Univariate Cox analysis also exposed in Table 2 esti-
mates a relative recurrence hazard of 11.59 and death
hazard of 23.86 for patients with the two markers altered
in comparison with patients having levels below the cut-
off points.
Multivariate analysis of the survival
Multivariate Cox analyses allow the assessment of which
variables give independent prognostic information among
the variables studied in relation to survival: age, gender,
tumour location, TNM classification, tumour differenti-
ation and the positivity of markers CA 72.4 and CEA (see
Table 3). We obtained a model where age, tumour location,
TNM stage and positivity of markers were the significant
covariables regarding recurrence hazard. When looking atTable 3 Multivariate Cox analysis and relative hazards for
recurrence and death in all patients
Feature Group Recurrence Death
RH 95% CI P RH 95% CI P
Age ≤75 1.00 Ref 0.021 1 Ref 0.001
>75 3.99 (1.23-12.95) 22.19 (3.46-142.49)
Location colon 1.00 Ref 0.020 1.00 Ref 0.151
rectum 3.73 (1.23-11.30) 2.65 (0.70-10.02)
TNM I + II 1.00 Ref 0.008 1.00 Ref 0.061
III 4.21 (1.45-12.23) 3.66 (0.94-14.22)
Positive
markers
None 1.00 Ref 1.00 Ref
1 7.93 (2.34-26.87) 0.001 55.18 (6.67-456.03) <0.001
2 14.62 (3.78-56.58) 0.000 79.84 (8.09-788.25) <0.001death hazards, only age and positivity of tumour markers
remained as independent prognostic factors.
Analysis of the survival of patients at stage II stratified by
tumour markers
The former univariate analyses made for all patients
were repeated for patients belonging to TNM stage II
stratified by tumour markers. Kaplan-Meier curves for
patients stratified by CA 72.4 and CEA levels are repre-
sented in Figure 1 (A1 and A2). Mean DFS, OS and the
percentages of tumour recurrence and death for each
marker are shown in Table 4. CA 72.4 clearly separates
the two groups of patients with different DFS and OS
(P < 0.001 and P = 0.005). Higher CA 72.4 levels are re-
lated to tumour recurrence and death percentages of
57.14% and 42.86%, against percentages of 9.09 and
6.06% when levels are below the cut-off. At this early
stage, CEA only achieves a borderline distinction in DFS
(P = 0.05) (Figure 1, B1 and B2).
The univariate Cox analysis exposed in Table 4 sum-
marizes the relative recurrence and death hazards for
patients at stage II classified by preoperative serum CA
72.4 or CEA levels. Those patients presenting CA 72.4
levels higher than 7 U/mL have relative recurrence and
death hazards of 9.39 and 8.40, whilst CEA exerts no
significant influence on these hazards.
Analysis of the survival of patients at stage II stratified by
the positivity of tumour markers
Data on DFS and OS, and univariate Cox analysis com-
paring the group of patients with at least one marker al-
tered versus reference group patients with no altered
levels of any tumour marker are displayed in Table 5.
Only one case of tumour recurrence and none of death
were reported on patients without increased levels of the
markers (DFS: 62.77 months). Prognosis worsens for
stage II patients with overexpressed levels of CA 72.4,
CEA or both, showing percentages of tumour recurrence
and death of 50% and 41.67%, associated with a very low
mean DFS and OS of 32.15 and 36.20 months, respect-
ively. The relative recurrence hazard was 21.52 times
higher than in patients with no altered levels. The death
hazard ratio could not be calculated because there was
A1) CA 72.4 – Disease Free Survival  
B1) CEA – Disease Free Survival   B2) CEA - Overall Survival 
A2) CA 72.4 – Overall Survival 
C1) CA 72.4 and/or CEA – Disease Free Survival C2) CA 72.4 and/or CEA – Overall Survival
Figure 1 Kaplan-Meier curves of CA 72.4 and CEA at stage II CRC. Kaplan Meier curves of 1) the disease free survival and 2) the overall
survival, for colorectal cancer patients that received curative resection of TNM stage II tumours, stratified by preoperative serum levels of A) CA
72.4, B) CEA and C) At least one or both markers with positive levels. D.F.S.: Disease free survival, O.S.: Overall survival. P: Statistical significance.
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tumour marker. Figure 1, C1 and C2 represent Kaplan-
Meier survival curves of this last analysis.
Discussion
CRC clinical research aims to obtain novel tools to im-
prove prognosis giving light in the decision-making re-
garding adjuvant chemotherapy. Specifically, identification
of reliable factors that improve selection of stage II
patients at high-risk of developing recurrence aftersurgery is of greatest importance [9]. In the current
study, we assessed the relevance of CA 72.4 in progno-
sis when measured in serum of patients before cura-
tive surgery.
DFS rates obtained in this study for TNM stages I-III
were highly similar to the ones obtained for Dukes sta-
ging, by others and in previous works of us, although
rates of death were a bit lower provided this work has
not included patients at TNM stage IV and it is a 5-year
survival study [24-27].
Table 4 DFS and OS rates stratified by tumour markers and univariate Cox analysis at stage II
D.F.S. O.S Univariate Cox analysis
Tumour marker Levels n Mean
(Months)
Recurrence% Mean
(Months)
Death% Recurrence Death
RH 95% CI RH 95% CI
CA 72.4 ≤ 7 33 59.89 9.09 61.40 6.06 1.00 (ref) 1.00 (ref)
U/mL > 7 7 30.61a 57.14 35.84b 42.86 9.39 (2.05-43.05)c 8.40 (1.40-50.43)d
CEA ≤ 10 33 58.21 12.12 60.05 9.09 1.00 (ref) 1.00 (ref)
ng/mL > 10 7 36.87e 42.86 39.89f 28.57 4.05 (0.90-18.23)g 3.44 (0.57-20.64)h
Abbreviations: DFS, disease free survival; OS, overall survival; RH, relative hazard; 95% CI, 95% confidence interval; ref, reference.
aP <0.0001, bP = 0.005, cP = 0.004, dP = 0.02, eP = 0.05, fP = 0.15, gP = 0.07, hP = 0.17.
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prognostic factor, with significantly higher recurrence and
death percentages for levels above 7 U/mL. These per-
centages exceeded the displayed by CEA, the standard for
CRC prognosis [28,29]. Univariate Cox analysis corrobo-
rated the superior value of prognostic information pro-
vided by CA 72.4, as recurrence and death are more
prone to occur with altered CA 72.4 levels. Nevertheless,
CEA complements the prognostic information offered by
CA 72.4 since recurrence and death are better predicted
when both markers are altered in the patients, being this
finding in agreement with the work of Louhimo [24].
Although studies on CA 72.4 in preoperative serum in
patients of CRC are very scarce [24,30], results agree on
the prognostic value of this marker. However, its per-
formance complementing CEA is not well established.
Multivariate Cox analysis was used to generate a model
that best explains the recurrence and death relative haz-
ards and test the prognostic independence of the variables
that influenced survival in univariate analysis. In addition
to TNM, age, tumour location and positivity of tumour
markers resulted significant. Positivity of tumour markers
is the strongest predictor for recurrence and death.
The current study aimed also to assess the prognostic
relevance of CA 72.4 at TNM stage II, to discriminate
those patients who are definitely cured after having a
curative resection of the tumour, from those that will
relapse or even die. Survival analysis confirmed the pre-
cise distinction of patients with different DFS and OS
by CA 72.4, whilst CEA has a non-significant effect on
the recurrence and death hazards, at this early stage.
Nevertheless, CEA contribution to prognosis predictionTable 5 DFS and OS rates stratified by positivity of tumour m
D.F.S.
Positive markers n Mean
(Months)
Recurrence% Me
(Mon
None 28 62.77 3.57 -
CEA and/or CA 72.4 12 32.15a 50.0 36.2
aP <0.001, bP <0.01.is not negligible, as shows the analysis taking into ac-
count the number of positive markers.
For years, efforts have been made on the search for
more effective predictors than the traditional staging
system not only across all CRC stages, but also regarding
early-stage CRC. Genetic and molecular markers that
could be useful for detecting who is or not at risk
emerged earlier [3,4,31-36]. Nowadays, a different ap-
proach based on the identification of clustered genetic
alterations and multimarker phenotypes is gaining wider
acceptance [36-38].
Conversely, studies dividing the TNM-stages into sub-
groups are rare. For instance, in a recent review to study
the clinical significance of circulating tumour cells in
non-metastatic CRC, Thorsteinsson and Jess [39] revised
9 studies and none of them had divided the TNM-stages
into subgroups. Recently, a multigene expression assay
has been developed to determine the relationship be-
tween quantitative tumour gene expression and the risk
of cancer recurrence at stage II. This quantitative multi-
gene expression assay is now marketed as Oncotype DX
Colon Cancer assay [40].
Unfortunately, to date, all these advances are not yet
being translated to the clinical routine, giving arguments
for implementation of CA 72.4 into clinical practice.
The present research has proved its prognostic relevance
that could complement the actual clinical classification
of patient prognosis based on the TNM system. This
marker has also proved to be valid to determine which
patients at stage II are in the high-risk category and
therefore should be given chemotherapy, and those who
will not have recurrent disease and are therefore in thearkers and univariate Cox analysis at stage II
O.S. Univariate Cox analysis
an
ths)
Death% Recurrence Death
RH 95% CI RH 95% CI
0 1.00 (ref) 1.00 (ref)
0 a 41.67 21.52b (2.53-182.86) - -
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markers, determination of CA 72.4 preoperative levels is
simple, without necessity of available tissue and cost-
effective, all of this corroborated by the fact that is
already employed in gastric cancer routine prognosis.
Conclusions
The present work has proved the prognostic relevance of
CA 72.4 at stage II CCR, and how in combination with
CEA allows the correct classification of nearly every patient
with bad prognosis. This could improve the decision-
making involved in the treatment of stage II colon cancer.
Further studies to assess the possible role of the
marker in the prediction of the effectiveness of treat-
ment are worthy.
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